HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir
Abstract
Recent clinical trials of direct-acting-antiviral agents (DAAs) against hepatitis C virus (HCV) achieved >90% sustained virological response (SVR) rates, suggesting that cure often took place before the end of treatment (EOT). We sought to evaluate retrospectively whether early response kinetics can provide the basis to individualize therapy to achieve optimal results while reducing duration and cost. 58 chronic HCV patients were treated with 12-week sofosbuvir + simeprevir (n = 19), sofosbuvir + daclatasvir (n = 19), or sofosbuvir + ledipasvir in three French referral centers. HCV was measured at baseline, day 2, every other week, EOT and 12 weeks post EOT. Furthermore, mathematical modeling was used to predict the time to cure, i.e., <1 virus copy in the entire extracellular body fluid. All but one patient who relapsed achieved SVR. Mean age was 60 ± 11 years, 53% were male, 86% HCV genotype-1, 9% HIV coinfected, 43% advanced fibrosis (F3), and 57% had cirrhosis. At weeks 2, 4 and 6, 48%, 88% and 100% of patients had HCV <15 IU/ml, with 27%, 74% and 91% of observations having target not detected, respectively. Modeling results predicted that 23 (43%), 16 (30%), 7 (13%), 5 (9%) and 3 (5%) subjects were predictedmore »
- Authors:
-
- Loyola Univ. Medical Center, Maywood, IL (United States). The Program for Experimental and Theoretical Modeling; Los Alamos National Lab. (LANL), Los Alamos, NM (United States). Theoretical Biology and Biophysics Group
- Loyola Univ. Medical Center, Maywood, IL (United States). The Program for Experimental and Theoretical Modeling; Univ. of Edinburgh, Scotland (United Kingdom). Center for Immunity
- Heidelberg Univ. (Germany). Cetner for Modeling and Simulation in the Biosciences
- Loyola Univ. Medical Center, Maywood, IL (United States). The Program for Experimental and Theoretical Modeling
- Univ. of Sao Paulo Hospital das Cinicas (Brazil)
- Alphabio Lab., Marseille (France)
- European Hospital, Marseille (France). Internal Medicine and Infectious Disease
- Saint Joseph Hospital, Marseille (France). Division of Hepatology
- CH Hyeres (France). Division of Hepatology
- Alphabio Lab., Marseille (France); European Hospital, Marseille (France). Internal Medicine and Infectious Disease
- Publication Date:
- Research Org.:
- Los Alamos National Laboratory (LANL), Los Alamos, NM (United States)
- Sponsoring Org.:
- USDOE; National Institutes of Health (NIH)
- OSTI Identifier:
- 1334130
- Alternate Identifier(s):
- OSTI ID: 1467524
- Report Number(s):
- LA-UR-15-27222
Journal ID: ISSN 0168-8278
- Grant/Contract Number:
- AC52-06NA25396; 1698:BB/L001330/1
- Resource Type:
- Accepted Manuscript
- Journal Name:
- Journal of Hepatology
- Additional Journal Information:
- Journal Volume: 64; Journal Issue: 6; Journal ID: ISSN 0168-8278
- Publisher:
- Elsevier
- Country of Publication:
- United States
- Language:
- English
- Subject:
- 59 BASIC BIOLOGICAL SCIENCES; Biological Science
Citation Formats
Dahari, Harel, Canini, Laetitia, Graw, Frederik, Uprichard, Susan L., Araújo, Evaldo S. A., Penaranda, Guillaume, Coquet, Emilie, Chiche, Laurent, Riso, Aurelie, Renou, Christophe, Bourliere, Marc, Cotler, Scott J., and Halfon, Philippe. HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir. United States: N. p., 2016.
Web. doi:10.1016/j.jhep.2016.02.022.
Dahari, Harel, Canini, Laetitia, Graw, Frederik, Uprichard, Susan L., Araújo, Evaldo S. A., Penaranda, Guillaume, Coquet, Emilie, Chiche, Laurent, Riso, Aurelie, Renou, Christophe, Bourliere, Marc, Cotler, Scott J., & Halfon, Philippe. HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir. United States. https://doi.org/10.1016/j.jhep.2016.02.022
Dahari, Harel, Canini, Laetitia, Graw, Frederik, Uprichard, Susan L., Araújo, Evaldo S. A., Penaranda, Guillaume, Coquet, Emilie, Chiche, Laurent, Riso, Aurelie, Renou, Christophe, Bourliere, Marc, Cotler, Scott J., and Halfon, Philippe. Wed .
"HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir". United States. https://doi.org/10.1016/j.jhep.2016.02.022. https://www.osti.gov/servlets/purl/1334130.
@article{osti_1334130,
title = {HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir},
author = {Dahari, Harel and Canini, Laetitia and Graw, Frederik and Uprichard, Susan L. and Araújo, Evaldo S. A. and Penaranda, Guillaume and Coquet, Emilie and Chiche, Laurent and Riso, Aurelie and Renou, Christophe and Bourliere, Marc and Cotler, Scott J. and Halfon, Philippe},
abstractNote = {Recent clinical trials of direct-acting-antiviral agents (DAAs) against hepatitis C virus (HCV) achieved >90% sustained virological response (SVR) rates, suggesting that cure often took place before the end of treatment (EOT). We sought to evaluate retrospectively whether early response kinetics can provide the basis to individualize therapy to achieve optimal results while reducing duration and cost. 58 chronic HCV patients were treated with 12-week sofosbuvir + simeprevir (n = 19), sofosbuvir + daclatasvir (n = 19), or sofosbuvir + ledipasvir in three French referral centers. HCV was measured at baseline, day 2, every other week, EOT and 12 weeks post EOT. Furthermore, mathematical modeling was used to predict the time to cure, i.e., <1 virus copy in the entire extracellular body fluid. All but one patient who relapsed achieved SVR. Mean age was 60 ± 11 years, 53% were male, 86% HCV genotype-1, 9% HIV coinfected, 43% advanced fibrosis (F3), and 57% had cirrhosis. At weeks 2, 4 and 6, 48%, 88% and 100% of patients had HCV <15 IU/ml, with 27%, 74% and 91% of observations having target not detected, respectively. Modeling results predicted that 23 (43%), 16 (30%), 7 (13%), 5 (9%) and 3 (5%) subjects were predicted to reach cure within 6, 8, 10, 12 and 13 weeks of therapy, respectively. The modeling suggested that the patient who relapsed would have benefitted from an additional week of sofosbuvir + ledipasvir. Adjusting duration of treatment according to the modeling predicts reduced medication costs of 43–45% and 17–30% in subjects who had HCV <15 IU/ml at weeks 2 and 4, respectively. Finally, the use of early viral kinetic analysis has the potential to individualize duration of DAA therapy with a projected average cost saving of 16–20% per 100-treated persons.},
doi = {10.1016/j.jhep.2016.02.022},
journal = {Journal of Hepatology},
number = 6,
volume = 64,
place = {United States},
year = {2016},
month = {6}
}
Web of Science
Works referenced in this record:
Hepatitis C
journal, March 2015
- Webster, Daniel P.; Klenerman, Paul; Dusheiko, Geoffrey M.
- The Lancet, Vol. 385, Issue 9973
HCV direct-acting antiviral agents: the best interferon-free combinations
journal, December 2013
- Schinazi, Raymond; Halfon, Philippe; Marcellin, Patrick
- Liver International, Vol. 34
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)
journal, April 2015
- Bourlière, Marc; Bronowicki, Jean-Pierre; de Ledinghen, Victor
- The Lancet Infectious Diseases, Vol. 15, Issue 4
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis: HEPATOLOGY, Vol. XX, No. X, 2015
journal, May 2015
- Reddy, K. Rajender; Bourlière, Marc; Sulkowski, Mark
- Hepatology, Vol. 62, Issue 1
Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection
journal, July 2014
- Sulkowski, Mark S.; Naggie, Susanna; Lalezari, Jacob
- JAMA, Vol. 312, Issue 4
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial
journal, June 2015
- Mizokami, Masashi; Yokosuka, Osamu; Takehara, Tetsuo
- The Lancet Infectious Diseases, Vol. 15, Issue 6
From non-A, non-B hepatitis to hepatitis C virus cure
journal, April 2015
- Pawlotsky, Jean-Michel; Feld, Jordan J.; Zeuzem, Stefan
- Journal of Hepatology, Vol. 62, Issue 1
The Cost-effectiveness, Health Benefits, and Financial Costs of New Antiviral Treatments for Hepatitis C Virus
journal, March 2015
- Rein, David B.; Wittenborn, John S.; Smith, Bryce D.
- Clinical Infectious Diseases, Vol. 61, Issue 2
Peginterferon Alfa-2a and Ribavirin for 24 Weeks in Hepatitis C Type 1 and 4 Patients With Rapid Virological Response
journal, August 2008
- Ferenci, Peter; Laferl, Hermann; Scherzer, Thomas–Matthias
- Gastroenterology, Vol. 135, Issue 2
Early Changes in Hepatitis C Virus (HCV) Levels in Response to Peginterferon and Ribavirin Treatment in Patients with Chronic HCV Genotype 1 Infection
journal, April 2009
- Hoofnagle, Jay H.; Wahed, Abdus S.; Brown, Jr., Robert S.
- The Journal of Infectious Diseases, Vol. 199, Issue 8
Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment-experienced patients
journal, June 2014
- Zeuzem, Stefan; DeMasi, Ralph; Baldini, Alessandra
- Journal of Hepatology, Vol. 60, Issue 6
Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics
journal, October 2014
- Dahari, Harel; Shteingart, Shimon; Gafanovich, Inna
- Liver International, Vol. 35, Issue 2
Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C
journal, February 2005
- Castéra, Laurent; Vergniol, Julien; Foucher, Juliette
- Gastroenterology, Vol. 128, Issue 2
FibroTest and FibroScan for the Prediction of Hepatitis C-Related Fibrosis: A Systematic Review of Diagnostic Test Accuracy
journal, November 2007
- Shaheen, Abdel Aziz M.; Wan, Alex F.; Myers, Robert P.
- The American Journal of Gastroenterology, Vol. 102, Issue 11, p. 2589-2600
Utilization of FibroScan in Clinical Practice
journal, January 2014
- Bonder, Alan; Afdhal, Nezam
- Current Gastroenterology Reports, Vol. 16, Issue 2
Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: The ANRS HCEP-23 study
journal, January 2012
- Zarski, Jean-Pierre; Sturm, Nathalie; Guechot, Jérôme
- Journal of Hepatology, Vol. 56, Issue 1
Evaluation of the COBAS® AmpliPrep/COBAS® TaqMan® HCV Test, v2.0 and comparison to assays used in routine clinical practice in an international multicenter clinical trial: The ExPECT study
journal, June 2015
- Kessler, Harald H.; Cobb, Bryan R.; Wedemeyer, Heiner
- Journal of Clinical Virology, Vol. 67
Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon- Therapy
journal, October 1998
- Neumann, A. U.
- Science, Vol. 282, Issue 5386
Maximum likelihood estimation in nonlinear mixed effects models
journal, June 2005
- Kuhn, E.; Lavielle, M.
- Computational Statistics & Data Analysis, Vol. 49, Issue 4
A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure
journal, May 2010
- Snoeck, E.; Chanu, P.; Lavielle, M.
- Clinical Pharmacology & Therapeutics, Vol. 87, Issue 6
Modelling how ribavirin improves interferon response rates in hepatitis C virus infection
journal, December 2004
- Dixit, Narendra M.; Layden-Almer, Jennifer E.; Layden, Thomas J.
- Nature, Vol. 432, Issue 7019
Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: Implications for treatment duration
journal, May 2011
- Guedj, Jeremie; Perelson, Alan S.
- Hepatology, Vol. 53, Issue 6
LP14 : A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: Optimist-1
journal, April 2015
- Kwo, P.; Gitlin, N.; Nahass, R.
- Journal of Hepatology, Vol. 62
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
journal, May 2014
- Kowdley, Kris V.; Gordon, Stuart C.; Reddy, K. Rajender
- New England Journal of Medicine, Vol. 370, Issue 20
P0843 : On-treatment viral kinetics do not predict SVR in patients with advanced liver disease receiving sofosbuvir in combination with daclatasvir or simeprevir for 12 weeks
journal, April 2015
- Hezode, C.; Chevaliez, S.; Scoazec, G.
- Journal of Hepatology, Vol. 62
P0872 : Early viral kinetics do not differ in patients with varying degrees of fibrosis and cirrhosis in the solar 1 trial
journal, April 2015
- Welzel, T. W.; Reddy, K. R.; Flamm, S. L.
- Journal of Hepatology, Vol. 62
Is resectable hepatocellular carcinoma a contraindication to liver transplantation? A novel decision model based on “number of patients needed to transplant” as measure of transplant benefit
journal, June 2014
- Vitale, A.; Cucchetti, A.; Qiao, G. L.
- Journal of Hepatology, Vol. 60, Issue 6
Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study
journal, March 2015
- Kohli, Anita; Osinusi, Anuoluwapo; Sims, Zayani
- The Lancet, Vol. 385, Issue 9973
Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy
journal, March 2015
- Sarrazin, Christoph; Wedemeyer, Heiner; Cloherty, Gavin
- Journal of Virological Methods, Vol. 214
Hepatitis C Virus RNA Levels During Interferon-Free Combination Direct-Acting Antiviral Treatment in Registrational Trials: Table 1.
journal, May 2015
- Harrington, Patrick R.; Deming, Damon J.; Komatsu, Takashi E.
- Clinical Infectious Diseases, Vol. 61, Issue 4
Effect of IL28B genotype on hepatitis B and C virus infection
journal, October 2015
- Stättermayer, Albert Friedrich; Ferenci, Peter
- Current Opinion in Virology, Vol. 14
Analysis of Hepatitis C Virus Decline during Treatment with the Protease Inhibitor Danoprevir Using a Multiscale Model
journal, March 2013
- Rong, Libin; Guedj, Jeremie; Dahari, Harel
- PLoS Computational Biology, Vol. 9, Issue 3
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life
journal, February 2013
- Guedj, J.; Dahari, H.; Rong, L.
- Proceedings of the National Academy of Sciences, Vol. 110, Issue 10
Individualized treatment for patients with low HCV load (Genotype 1): A viral kinetic approach
journal, April 2014
- Dahari, Harel; Cotler, Scott J.
- Hepatology, Vol. 59, Issue 6
Works referencing / citing this record:
Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis
journal, December 2018
- Gambato, Martina; Canini, Laetitia; Lens, Sabela
- Liver International, Vol. 39, Issue 5
Utility of viral kinetics in HCV therapy – It is not over until it is over?
journal, February 2019
- Sandmann, Lisa; Manns, Michael P.; Maasoumy, Benjamin
- Liver International, Vol. 39, Issue 5
Management of acute HCV infection in the era of direct-acting antiviral therapy
journal, May 2018
- Martinello, Marianne; Hajarizadeh, Behzad; Grebely, Jason
- Nature Reviews Gastroenterology & Hepatology, Vol. 15, Issue 7
Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study)
journal, December 2017
- Rosenthal, E.; Fougerou-Leurent, C.; Renault, A.
- HIV Medicine, Vol. 19, Issue 3
Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era
journal, August 2018
- Raja, Rubesh; Baral, Subhasish; Dixit, Narendra M.
- Immunological Reviews, Vol. 285, Issue 1
Ribavirin facilitates early viral kinetics in chronic hepatitis C patients receiving daclatasvir/asunaprevir
journal, July 2019
- Huang, Chung‐Feng; Yeh, Ming‐Lun; Huang, Ching‐I
- Journal of Gastroenterology and Hepatology, Vol. 35, Issue 1
A Parameter Estimation Method for Multiscale Models of Hepatitis C Virus Dynamics
journal, July 2019
- Reinharz, Vladimir; Churkin, Alexander; Lewkiewicz, Stephanie
- Bulletin of Mathematical Biology, Vol. 81, Issue 10
Plasma Hepatitis E Virus Kinetics in Solid Organ Transplant Patients Receiving Ribavirin
journal, July 2019
- Lhomme, Sebastien; DebRoy, Swati; Kamar, Nassim
- Viruses, Vol. 11, Issue 7
Modelling how responsiveness to interferon improves interferon-free treatment of hepatitis C virus infection
journal, July 2018
- Venugopal, Vishnu; Padmanabhan, Pranesh; Raja, Rubesh
- PLOS Computational Biology, Vol. 14, Issue 7
Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection
journal, May 2018
- Martinello, M.; Bhagani, S.; Gane, E.
- Journal of Viral Hepatitis, Vol. 25, Issue 10
Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in Brazil
journal, November 2017
- Perazzo, Hugo; Jorge, Marcelino Jose; Silva, Julio Castro
- BMC Gastroenterology, Vol. 17, Issue 1
The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?
journal, August 2017
- Nguyen, Thi Huyen Tram; Guedj, Jérémie; Uprichard, Susan L.
- Scientific Reports, Vol. 7, Issue 1
Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in Brazil
journal, November 2017
- Perazzo, Hugo; Jorge, Marcelino Jose; Silva, Julio Castro
- BMC Gastroenterology, Vol. 17, Issue 1
Modelling how responsiveness to interferon improves interferon-free treatment of hepatitis C virus infection
journal, July 2018
- Venugopal, Vishnu; Padmanabhan, Pranesh; Raja, Rubesh
- PLOS Computational Biology, Vol. 14, Issue 7
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens
journal, May 2017
- Cento, Valeria; Nguyen, Thi Huyen Tram; Di Carlo, Domenico
- PLOS ONE, Vol. 12, Issue 5
HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients
journal, December 2017
- Canini, Laetitia; Imamura, Michio; Kawakami, Yoshiiku
- PLOS ONE, Vol. 12, Issue 12
Very rapid virologic response and early HCV response kinetics, as quick measures to compare efficacy and guide a personalized response-guided therapy
journal, August 2016
- Yakoot, Mostafa; Abdo, Alaa; Yousry, Ahmed
- Drug Design, Development and Therapy, Vol. Volume 10
A Robust and Efficient Numerical Method for RNA-Mediated Viral Dynamics
journal, October 2017
- Reinharz, Vladimir; Churkin, Alexander; Dahari, Harel
- Frontiers in Applied Mathematics and Statistics, Vol. 3
Mathematical Analysis of Viral Replication Dynamics and Antiviral Treatment Strategies: From Basic Models to Age-Based Multi-Scale Modeling
journal, July 2018
- Zitzmann, Carolin; Kaderali, Lars
- Frontiers in Microbiology, Vol. 9
Plasma Hepatitis E Virus Kinetics in Solid Organ Transplant Patients Receiving Ribavirin
journal, July 2019
- Lhomme, Sebastien; DebRoy, Swati; Kamar, Nassim
- Viruses, Vol. 11, Issue 7
Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C genotype 1b
journal, January 2017
- Endo, Daisuke; Satoh, Kenichi; Shimada, Noritomo
- World Journal of Gastroenterology, Vol. 23, Issue 13
Assessment of lncRNA GAS5, lncRNA HEIH, lncRNA BISPR and its mRNA BST2 as serum innovative non-invasive biomarkers: Recent insights into Egyptian patients with hepatitis C virus type 4
journal, January 2020
- Samaloty, Nourhan M. El; Shabayek, Marwa I.; Ghait, Ramy S.
- World Journal of Gastroenterology, Vol. 26, Issue 2
Viral hepatitis C treatment shortening – what is the limit?
journal, January 2019
- Zarębska-Michaluk, Dorota
- Clinical and Experimental Hepatology, Vol. 5, Issue 4